Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment

Award Number: R03AG098738
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment - ABSTRACT Alzheimer’s disease (AD) affects millions in the United States, with cases expected to further surge in the coming decades. There are no treatments currently available to halt or reverse AD progression, which indicates the urgent need for preventions before the onset of AD. Mild cognitive impairment (MCI), often considered as a potential precursor to AD, presents a critical window for preventive strategies. However, FDA-approved treatments for MCI are limited to recently approved anti-amyloid monoclonal antibodies (mAbs), which are costly. Given this, additional therapeutic options are needed to expand treatment choices for patients. Glucagon-like peptide-1 (GLP-1) agonists, originally developed for type 2 diabetes, have demonstrated potential neuroprotective effects, including reducing neuroinflammation. However, their long-term impact on AD prevention remains unclear, with concerns regarding safety and cost- effectiveness. The central hypothesis of this project is that GLP-1 agonists can reduce the risk of AD progression in MCI patients while maintaining an acceptable safety profile and cost -effectiveness. To investigate this, we propose two specific aims: (1) to evaluate the effectiveness of GLP-1 agonists in preventing AD progression compared to non-users and anti-amyloid mAb users, and (2) to assess the safety of GLP-1 agonists in MCI patients. In addition, an exploratory aim will assess the cost-effectiveness of GLP-1 agonists compared to non-users and anti-amyloid mAb users. This study will use real-world data (RWD) from TriNetX and employ a target trial emulation (TTE) framework to generate high-quality comparative evidence. By integrating real-world effectiveness, safety, and economic evaluations, this project will provide critical insights to guide clinical decision-making and future trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $324,000 )
2026	2026	CINCINNATI UNIV OF	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Aging Research	000	1	2/5/2026	NEW	$324,000
														Subtotal = $324,000

Grand Total All Awards = $324,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment

Award Number: R03AG098738

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer